cll

CLEC12A MICL CLL-1 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 41~45 kDa and the accession number is EAW96132.1.

Expression system: HEK293 Cells
Length: 65-265, Extracellular Domain
Activity: ELISA

Expression system: HEK293 Cells
Length: 65-265, Extracellular Domain
Activity: ELISA

CLEC12A MICL CLL-1 Protein, Human, Recombinant (Avi & Fc), Biotinylated is expressed in HEK293 mammalian cells with AVI and Fc tag. The predicted molecular weight is 51.61 kDa and the accession number is EAW96132.1.

CLEC12A MICL CLL-1 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 25.12 kDa and the accession number is NP_808354.1.

CLEC12A MICL CLL-1 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 50.38 kDa and the accession number is EAW96132.1.

Expression system: HEK293 Cells
Length: 65-265, Extracellular Domain
Activity: ELISA

Expression system: HEK293 Cells
Length: 65-265, Extracellular Domain
Activity: ELISA

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. CLEC12A MICL CLL-1 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weight is 24.6 kDa and the accession number is A0A2K5WXQ6.

Expression system: HEK293 Cells
Length: 65-267, Extracellular Domain
Activity: Not Tested

Expression system: HEK293 Cells
Length: 65-265, Extracellular Domain
Activity: Not Tested

SHISA3(high)CLL are characterized by a restrained activation of Wnt signaling and sensibility to lenalidomide-induced apoptosis. SHISA3 promoter hypermethylation might increase the risk of LSCC through regulation of gene expression and is a potential diagnostic and prognostic biomarker for LSCC. Shisa3 is a novel tumor suppressor identified in lung cancer. SHISA3 gene is epigenetically inactivated in a substantial fraction of CRC, and its hypermethylation is of prognostic significance in predicting clinical outcome.

Expression system: HEK293 Cells
Length: 1-395, Partial
Activity: Not Tested

Expression system: E. coli
Length: 1-530, Full Length
Activity: Not Tested

Expression system: HEK293 Cells
Length: 22-225, Partial
Activity: Not Tested

Expression system: E. coli
Length: 1-233, Full Length
Activity: Not Tested

YTHDF2 Protein, Human, Recombinant (His) is expressed in E. coli. The accession number is Q9Y5A9.

The protein encoded by this gene is an evolutionarily conserved 95-kDa protein containing six C-terminal zinc-finger motifs and an N-terminal POZ domain. It has been reported that BCL-6 is present in DNA-binding complexes in nuclear extracts from various B-cell lines. There are many relationships between non-Hodgkin's lymphoma, diffuse large cell lymphoma and BCL6's translocations. BCL6 can repress transcription from promoters linked to its DNA target sequence and this activity is dependent upon specific DNA-binding and the presence of an intact N-terminal half of the protein.

Expression system: E. coli
Length: 713-853, Partial
Activity: Not Tested

BCL2 (B-cell leukemia lymphoma 2, N-Histidine-tagged), also known as Bcl-2, belongs to the Bcl-2 family. Bcl-2 family proteins regulate and contribute to programmed cell death or apoptosis. It is a large protein family and all members contain at least one of four BH (bcl-2 homology) domains. Certain members such as Bcl-2, Bcl-xl and Mcl1 are anti-apoptotic, whilst others are pro-apoptotic. Most Bcl-2 family members contain a C-terminal transmembrane domain that functions to target these proteins to the outer mitochondrial and other intracellular membranes. It is expressed in a variety of tissues. BCL2 blocks the apoptotic death of some cells such as lymphocytes. It also regulates cell death by controlling the mitochondrial membrane permeability and inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and or by binding to the apoptosis-activating factor. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Expression system: E. coli
Length: 1-303, Full Length
Activity: Not Tested

Expression system: E. coli
Length: 147-227, Partial
Activity: Not Tested